Segui
Andrea Bonetti MD
Andrea Bonetti MD
Ospedale Mater Salutis Legnago Italy
Email verificata su aulsslegnago.it
Titolo
Citata da
Citata da
Anno
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, ...
Journal of Clinical Oncology 41 (33), 5080-5089, 2023
50432023
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ...
J clin oncol 27 (19), 3109-3116, 2009
27002009
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial
C Aschele, L Cionini, S Lonardi, C Pinto, S Cordio, G Rosati, S Artale, ...
J Clin Oncol 29 (20), 2773-2780, 2011
9382011
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
2512020
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer …
A Paccagnella, MG Ghi, L Loreggian, A Buffoli, H Koussis, CA Mione, ...
Annals of oncology 21 (7), 1515-1522, 2010
2142010
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of …
MJ Piccart, JA Green, AJ Lacave, N Reed, I Vergote, P Benedetti-Panici, ...
Journal of clinical oncology 18 (6), 1193-1202, 2000
1962000
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years
A De Gramont, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, ...
Journal of Clinical Oncology 25 (18_suppl), 4007-4007, 2007
1942007
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ...
Annals of Oncology 26 (4), 724-730, 2015
1892015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results …
C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ...
Annals of oncology 26 (6), 1188-1194, 2015
1882015
Platinum antitumor complexes: 50 years since Barnett Rosenberg’s discovery
FM Muggia, A Bonetti, JD Hoeschele, M Rozencweig, SB Howell
J. Clin. Oncol 33 (35), 4219-4226, 2015
1862015
Ki‐67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis
A Molino, R Micciolo, M Turazza, F Bonetti, Q Piubello, A Bonetti, R Nortilli, ...
International journal of cancer 74 (4), 433-437, 1997
1751997
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial
MG Ghi, A Paccagnella, D Ferrari, P Foa, D Alterio, C Codecà, F Nolè, ...
Annals of Oncology 28 (9), 2206-2212, 2017
1742017
Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years
A De Gramont, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, ...
Journal of Clinical Oncology 23 (16_suppl), 3501-3501, 2005
1662005
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma
E Bajetta, M Di Bartolomeo, L Mariani, A Cassata, S Artale, S Frustaci, ...
Cancer 100 (2), 279-287, 2004
1622004
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
1552022
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol
P Perego, S Romanelli, N Carenini, I Magnani, R Leone, A Bonetti, ...
Annals of Oncology 9 (4), 423-430, 1998
1131998
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ...
Annals of Oncology 30 (5), 766-773, 2019
1062019
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
E Bajetta, I Floriani, M Di Bartolomeo, R Labianca, A Falcone, ...
Annals of oncology 25 (7), 1373-1378, 2014
1062014
bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer.
A Bonetti, M Zaninelli, R Leone, GL Cetto, G Pelosi, S Biolo, A Menghi, ...
Clinical cancer research: an official journal of the American Association …, 1998
1011998
Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis
A Molino, G Pelosi, M Turazza, L Sperotto, A Bonetti, R Nortilli, G Fattovich, ...
Breast cancer research and treatment 42, 23-30, 1997
921997
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20